Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 304

Sort by

Sort Order Select

Journal Articles

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha D. Tangada, William Savage, Bruce Ewenstein

Blood (2021) 137 (13): 1818–1827.

https://doi.org/10.1182/blood.2020005673

Published: 2021

Includes: Supplemental data

Journal Articles

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Hanny Al-Samkari, Rebecca S. Karp Leaf, Walter H. Dzik, Jonathan C. T. Carlson, Annemarie E. Fogerty, Anem Waheed, Katayoon Goodarzi, Pavan K. Bendapudi, Larissa Bornikova, Shruti Gupta, David E. Leaf, David J. Kuter, Rachel P. Rosovsky

Blood (2020) 136 (4): 489–500.

https://doi.org/10.1182/blood.2020006520

Published: 2020

Includes: Supplemental data

Journal Articles

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Katharina Holstein, Xiaofei Liu, Andrea Smith, Paul Knöbl, Robert Klamroth, Ulrich Geisen, Hermann Eichler, Wolfgang Miesbach, Andreas Tiede

Blood (2020) 136 (3): 279–287.

https://doi.org/10.1182/blood.2019003639

Published: 2020

Includes: Supplemental data

Journal Articles

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupancic-Salek, Johannes Oldenburg

Blood (2019) 134 (22): 1973–1982.

https://doi.org/10.1182/blood.2019001542

Published: 2019

Includes: Multimedia, Supplemental data

Journal Articles

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Blood (2019) 134 (Supplement_1): 2361.

https://doi.org/10.1182/blood-2019-122237

Published: 2019

Journal Articles

Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study

Ri Liesner, Ellis J. Neufeld, MD

Blood (2019) 134 (Supplement_1): 903.

https://doi.org/10.1182/blood-2019-125520

Published: 2019

Journal Articles

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

Jordan K Schaefer, MD, Yun Li, PhD, Xiaowen Kong, MA, Tina Alexandris-Souphis, RN, Mona A Ali, PharmD, Brian Haymart, RN, MS, Scott Kaatz, DO, MSc, Eva Kline-Rogers, RN, MS, Jay H Kozlowski, MD, Gregory D Krol, Sahana R Shankar, Suman L Sood, MD, James B Froehlich, MD MPH, Geoffrey D Barnes, MD MSc

Blood (2019) 134 (Supplement_1): 787.

https://doi.org/10.1182/blood-2019-122526

Published: 2019

Journal Articles

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Alfonso J Tafur, MD MS, Na Li, PhD, Nathan Clark, PharmD, Sam Schulman, MD PhD FRCPC, Alex Spyropoulos, MD, Joseph A Caprini, MD MS, FACS, RVT, James Douketis, MD

Blood (2019) 134 (Supplement_1): 710.

https://doi.org/10.1182/blood-2019-125292

Published: 2019

Journal Articles

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays

Hande Kizilocak, Elizabeth Marquez-Casas, BS, Jemily Malvar, MS, Roxana Carmona, MD, Guy Young, MD

Blood (2019) 134 (Supplement_1): 1134.

https://doi.org/10.1182/blood-2019-123820

Published: 2019

Journal Articles

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Gita Massey, Michael F. Guerrera, MD, Lance Ballester, MS, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 1137.

https://doi.org/10.1182/blood-2019-122569

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Amy Shapiro, Giancarlo Castaman, MD, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, MD, Silva Zupancic-Salek, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 1139.

https://doi.org/10.1182/blood-2019-122809

Published: 2019

Journal Articles

Practice Patterns and Clinical Outcomes of Platelet Alloimmunization in a Comprehensive Cancer Center

Rohit V Goswamy, MD, Daniel J Tannenbaum, MD, Fleur M. Aung, MD, Cristhiam Mauricio Rojas Hernandez, MD

Blood (2019) 134 (Supplement_1): 1170.

https://doi.org/10.1182/blood-2019-131837

Published: 2019

Journal Articles

Two Different Platelet Thresholds for Bleeding Prophylaxis in Children with Malignancies or Non-Malignant Disorders: The Bambino Gesù Children's Hospital Experience

Pierpaolo Berti, MD, Guglielmo Trua, MD, Francesco Lamura, MD, Laila Costantino, MD, Costantino Damico, MD, Alessandra Paoloni, MD, Maria Teresa Romano, MD, Katia Girardi, MD, Luisa Strocchio, MD, Elisabetta Cicchetti, Alessandra Bernardi, Valentina De Nava, Antonio Cappelli, Andrea Onetti Muda, MD PhD, Mauro Montanari, MD

Blood (2019) 134 (Supplement_1): 1173.

https://doi.org/10.1182/blood-2019-129132

Published: 2019

Journal Articles

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

Wolfgang A. Miesbach, Giovanni Di Minno, Elena Santagostino, Dr. Klamroth, Inga Bayh, Amaryllis Soto, Cedric Hermans

Blood (2019) 134 (Supplement_1): 1117.

https://doi.org/10.1182/blood-2019-128486

Published: 2019

Journal Articles

Low-Dose Immune Tolerance Induction for Hemophilia a Children with Poor-Risk High-Titer Inhibitors

Zekun Li, MBBS, Zhenping Chen, PhDMD, Xiaoling Cheng, Xinyi Wu, Li Gang, Zhen Yingzi, Cai Siyu, Man-Chiu Poon, Runhui Wu, MD PhD

Blood (2019) 134 (Supplement_1): 1122.

https://doi.org/10.1182/blood-2019-132021

Published: 2019

Journal Articles

Impact of Systematic Pharmacokinetic (PK) Profiles in a Cohort of 29 Patients Treated with Conventional and Extended-Half Life (EHL) Products

Teresa Ceglie, Berardino Pollio, Irene Ricca, Maria Messina, Claudia Linari, Mauro Pagliarino

Blood (2019) 134 (Supplement_1): 1123.

https://doi.org/10.1182/blood-2019-132199

Published: 2019

Journal Articles

The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis

Leonard Naymagon, MD, Douglas Tremblay, MD, Nicole Zubizarreta, MPH, Erin Moshier, MS, Thomas Schiano, MD, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 1154.

https://doi.org/10.1182/blood-2019-124042

Published: 2019

Journal Articles

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Paulette Bryant, MD, Jenny McDaniel, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD MSc

Blood (2019) 134 (Supplement_1): 1126.

https://doi.org/10.1182/blood-2019-126659

Published: 2019

Journal Articles

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Jonathan M. Ducore, MD MPH, Shadan Lalezari, PhD, Elena Santagostino, MD PhD, Sanjay P Ahuja, MD, Monika Maas Enriquez, Claudia Tueckmantel, PhD, Mark Reding

Blood (2019) 134 (Supplement_1): 1129.

https://doi.org/10.1182/blood-2019-123947

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study

Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study

Impact of Adding Aspirin to Direct Oral Anticoagulant Therapy without an Apparent Indication

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Practice Patterns and Clinical Outcomes of Platelet Alloimmunization in a Comprehensive Cancer Center

Two Different Platelet Thresholds for Bleeding Prophylaxis in Children with Malignancies or Non-Malignant Disorders: The Bambino Gesù Children's Hospital Experience

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

Low-Dose Immune Tolerance Induction for Hemophilia a Children with Poor-Risk High-Titer Inhibitors

Impact of Systematic Pharmacokinetic (PK) Profiles in a Cohort of 29 Patients Treated with Conventional and Extended-Half Life (EHL) Products

The Use of Direct Oral Anticoagulants in Non-Cirrhotic Portal Vein Thrombosis

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only